🔎 Trials Near Me

Home › Triple-Negative Breast Cancer › New York › Staten Island

Triple-Negative Breast Cancer clinical trials in Staten Island, NY

5 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Staten Island (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

RecruitingPhase 1
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown · 12 mi away
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06246968

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

RecruitingPhase 2
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown · 12 mi away
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05570253

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

RecruitingPhase 2
  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities), Middletown · 12 mi away
Ages 70 and older · All sexes · Updated Aug 17, 2026 · NCT07768436

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

RecruitingPhase 2
  • Memorial Sloan Kettering Monmouth, Middletown · 12 mi away
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT03808337

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

RecruitingPhase 2
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown · 12 mi away
Ages 18 and older · Women · Updated Feb 17, 2026 · NCT04683679

Triple-Negative Breast Cancer trials in other cities

Other studies in Staten Island

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.